(April 1, 2024 - March 31, 2025)
（TSE：4548）
-
FY2024 Results P3-7
Overview
Domestic Pharmaceuticals
Overseas Pharmaceuticals
Bulk Products / CDMO, Royalty, LAL Business
Trend in R&D Expenses
- FY2025 Forecasts P8-12
Overview
Domestic Pharmaceuticals
Overseas Pharmaceuticals
Bulk Products / CDMO, Royalty, LAL Business
-
Research and Development P13-18
SI-6603 (Lumbar disc herniation)
Gel-One (Osteoarthritis of the knee and the hip)
SI-722(Interstitial cystitis and bladder pain syndrome)
SI-449 (Adhesion Barrier)
- Other Topics P19-22
-
Research and Development P13-18
Status of Application for Approval of SI-6603 in the United
States
Progress Against the Mid-Term Management Plan in Fiscal 2024
Basic Policy on Profit Distribution
This material contains forward-looking statements regarding future management strategies or performance forecasts. These statements are based on judgments derived from information that is currently available to Seikagaku and are subject to risk and uncertainty. Actual results and developments may differ significantly from these forward-looking statements due to various factors.
Information about pharmaceutical products or medical devices (including products currently in development)
included in this material is not intended to constitute an advertisement or medical advice. 2
Contents
E x p l o r i n g t h e I n n o v a t i v e P r o m i s e o f G l y c o s c i e n c e
E x p l o r i n g t h e I n n o v a t i v e
FY2024 Results
P r o m i s e o f G l y c o s c i e n c e
3
Net sales: Up 8.7% on increases in royalty income, and higher sales in the LAL business
Operating Income: Up 207.8% due to the revenue increase
Ordinary Income: Up 14.3%, below operating income growth because of recognition of foreign exchange loss
Net Income: Down 44.5% due to higher tax expenses
Net Sales by Business Segment
Overseas Sales Ratio
（Millions of Yen）
FY 2023
Results
FY 2024
Results
% of
Change
+8.7%
Net Income
36,213
39,374
Operating Income
433
1,333
+207.8%
Ordinary
Income
1,691
1,933
+14.3%
Net Income
2,186
1,214
-44.5%
Net Income
per Share
¥40.08
¥22.25
ー
+8.7％
(Millions of Yen)
FY 2023
Other Performance
FY 2023 FY 2024 % of
10,059
9,804
12,100
11,919
36,213
3,083
39,374
39.7%
60.3%
LAL
38.0%
62.0%
11,860
2,598
3,192
FY 2024
Domestic Overseas
Indicators Change
699
R& D Expenses
（Millions of Yen）
Ratio of R& D expenses to sales
( excluding royalty income)
Exchange rate at end of period (US$1）
Ave. exchange rate during
the period (US$1 ）
7,484 7,643 +2.1%
21.1％ 20.8％ -0.3pt
¥151.4 ¥149.5 -¥1.9
¥144.6 ¥152.6 +¥8.0
10,271
FY 2023 FY 2024
Domestic Overseas
*excluding royalty income
4
FY2024 Results
Overview
E x p l o r i n g t h e I n n o v a t i v e P r o m i s e o f G l y c o s c i e n c e
FY2024 Results
Domestic Pharmaceuticals
Net sales down 1.5％ year on year due to lower sales of ARTZ and the OPEGAN series
Sales Comparison
ARTZ（Joint-function improving agent）
E x p l o r i n g t h e I n n o v a t i v e P r o m i s e o f G l y c o s c i e n c e
(Millions of Yen)
-1.5％
Market share: Up on higher deliveries to medical institutions (Approx 83%*)
Seikagaku sales: Facilities maintenance for the purpose of production system expansion at the Company's plant was completed, and shipment volume increased year
12,100 11,919
FY 2023 FY 2024
on year. However, the Company's sales declined year on year due to a
decrease in unit prices reductions.
OPEGAN series（Ophthalmic viscoelastic devices）
Market share: At the prior-year level because of higher deliveries to medical
institutions and market growth (Approx 51%*)
Seikagaku sales: Down due to a decline in unit prices
Other Products（Seikagaku sales）
Hernicore: Down due to shipment timing
MucoUp: Down due to the impact of an NHI reimbursement price change
JOYCLU: Up due to shipment timing
Continued to gather side effects reports and other information on JOYCLU and provide
safety-related information.
5
*Source：Copyright © 2025 IQVIA. Calculated based on JPM April 2023 - March 2025 by SKK , Reprinted with permission